The Online Investor
Albany Molecular Research Inc (AMRI)

Albany Molecular Research is a contract research and manufacturing organization providing customers integrated drug discovery, development, and manufacturing services. Co. has three segments: Discovery and Development Services, which include provides a range of chemical development technologies for route development; Active Pharmaceutical Ingredients, which provides chemical synthesis and manufacturing services for its customers; drug product, which provides facilities to deliver integrated pharmaceutical drug development programs and services; and Fine Chemicals, which provides lab to commercial scale synthesis of reagents and diverse compounds to the pharmaceutical, among others.
Company Name: 
Albany Molecular Research Inc
Website: 
www.amriglobal.com
Sector: 
Biotechnology
Quotes delayed 20 minutes



Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Albany Molecular Research Inc (AMRI) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.